Yes. Hematopoietic stem cell transplant (HSCT) is a fully established, regulated procedure performed at accredited Chinese hospitals. Mesenchymal stem cell (MSC) programs are offered under hospital-approved clinical protocols at NMPA-registered facilities with GMP-certified cell labs. SinoCareBridge only partners with hospitals that meet these standards. We do not work with unregulated clinics offering unproven "stem cell tourism" treatments.

Costs vary significantly by therapy type: MSC therapy typically ranges USD 15,000–40,000 per treatment cycle, depending on cell source, number of infusions, and condition. HSCT (bone marrow transplant) ranges USD 50,000–150,000+, depending on autologous vs. allogeneic, hospital level, and complication management. We provide itemized quotes after medical record review — no hidden hospital commissions.

MSC therapy uses mesenchymal stem cells (often from umbilical cord or adipose tissue) delivered via IV or injection to reduce inflammation and support tissue repair. It is minimally invasive, outpatient or short-stay, and used for degenerative and autoimmune conditions. HSCT (bone marrow transplant) is a more intensive procedure involving high-dose chemotherapy followed by infusion of blood-forming stem cells. It is used for blood cancers and severe immune disorders, requires hospitalization, and is a well-established curative-intent treatment.

Eligibility depends on your specific condition, disease stage, prior treatments, and overall health. For HSCT, criteria are well-defined (e.g., multiple myeloma patients eligible for autologous transplant). For MSC therapy, suitability is assessed case-by-case. The first step is to send your medical records — our clinical team reviews them and provides a candid assessment, including whether stem cell therapy is appropriate or whether other treatments should be prioritized. There is no charge for initial record review.

For MSC therapy: typically 1–2 weeks, including pre-treatment assessment, 1–3 infusions, and post-treatment observation. For HSCT: 4–8 weeks total, including 2–4 weeks in-hospital for conditioning and transplant, plus 2–4 weeks of outpatient recovery before clearance to travel home. Your coordinator provides a detailed timeline after treatment planning.

MSC therapy is generally well-tolerated; common side effects are mild and short-lived (headache, fatigue, low-grade fever). Serious adverse events are rare at accredited facilities. HSCT carries more significant risks, including infection, graft-versus-host disease (allogeneic), and organ toxicity — these are carefully managed in specialized transplant units. Your physician will discuss risks specific to your condition and treatment plan before any procedure. We encourage patients to seek second opinions and make informed decisions.